Stockscreener 앱 받기
0.3501
0.03%
0.0001
시간 외 거래:
.34
-0.0101
-2.88%
전일 마감가:
$0.35
열려 있는:
$0.3453
하루 거래량:
438.59K
Relative Volume:
1.74
시가총액:
$22.00M
수익:
$37.20M
순이익/손실:
$-11.85M
주가수익비율:
-1.8349
EPS:
-0.1908
순현금흐름:
$-10.59M
1주 성능:
+4.32%
1개월 성능:
-7.23%
6개월 성능:
-55.68%
1년 성능:
-64.11%
1일 변동 폭
$0.3366
$0.3697
1주일 범위
$0.3115
$0.4717
52주 변동 폭
$0.3003
$1.04
Cytosorbents Corp Stock (CTSO) Company Profile
명칭
Cytosorbents Corp
전화
973-329-8885
주소
305 COLLEGE ROAD EAST, PRINCETON, NJ
Compare CTSO vs ABT, MDT, SYK, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CTSO
Cytosorbents Corp
|
0.3501 | 19.55M | 37.20M | -11.85M | -10.59M | -0.1908 |
ABT
Abbott Laboratories
|
108.33 | 197.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
94.17 | 118.14B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
303.13 | 125.70B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
47.80 | 71.55B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
89.90 | 51.78B | 6.30B | 1.07B | 1.09B | 1.8406 |
Cytosorbents Corp Stock (CTSO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-09-07 | 개시 | B. Riley Securities | Buy |
| 2021-10-14 | 재개 | B. Riley Securities | Buy |
| 2020-09-17 | 개시 | Jefferies | Buy |
| 2020-09-01 | 개시 | SVB Leerink | Outperform |
| 2017-08-08 | 재확인 | Maxim Group | Buy |
| 2016-10-26 | 개시 | Aegis Capital | Buy |
| 2016-05-24 | 개시 | Maxim Group | Buy |
| 2015-10-29 | 업그레이드 | WBB Securities | Speculative Buy → Buy |
| 2015-05-12 | 재확인 | MLV & Co | Buy |
| 2015-04-01 | 재확인 | MLV & Co | Buy |
| 2015-03-05 | 개시 | MLV & Co | Buy |
| 2015-02-25 | 개시 | WBB Securities | Speculative Buy |
| 2015-01-27 | 재확인 | H.C. Wainwright | Buy |
모두보기
Cytosorbents Corp 주식(CTSO)의 최신 뉴스
CytoSorbents to present at Moody Capital Soluti... - Pluang
CytoSorbents to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference - The Globe and Mail
CytoSorbents Plans 1-for-20 Reverse Stock Split to Maintain Nasdaq Listing - citybiz
CytoSorbents to implement 1-for-20 reverse stoc... - Pluang
CytoSorbents Announces Reverse Stock Split - PR Newswire
CTSO Looks 61.4% Undervalued on GF Value™ Amid Challenging Funda - GuruFocus
A blood-cleansing device was linked to 37% less severe bleeding in urgent heart surgery - Stock Titan
Cytosorbents Earnings Call Balances Progress and Risk - TipRanks
Cytosorbents (CTSO) Financial Update: EPS Comes in Below Forecast; Market Follow-Through: Shares Finish 4.56% LowerEarnings Season Outlook - vinanet.vn
CytoSorbents (CTSO) wins approval for reverse split and director slate at 2026 meeting - Stock Titan
Cytosorbents (CTSO) Q2 2026 Earnings Call Transcript - The Globe and Mail
Cytosorbents Corp. R (HQE1.DU) Q1 FY2026 earnings call transcript - Yahoo Finance
Cytosorbents Corp (CTSO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Q2 2026 Cytosorbents Corp Earnings Call Transcript - GuruFocus
Cytosorbents Corp (CTSO) Stock News Today - TradingKey
CytoSorbents posts $9.6M Q2 revenue, narrows cash burn and advances DrugSorb-ATR regulatory path - TradingView
Cytosorbents Corporation Q2 2026 Earnings Call Summary - Yahoo Finance
CytoSorbents Corp (CTSO) (Q2 2026) Earnings Call Highlights: Nea - GuruFocus
Is CytoSorbents Corp (CTSO) a Value Opportunity After Q2 Earning - GuruFocus
CytoSorbents Corp (CTSO) (Q2 2026) Earnings Call Highlights: Nearing Breakeven with Strong ... - finance.yahoo.com
Earnings call transcript: Cytosorbents posts modest Q2 2026 revenue beat - Investing.com
Cytosorbents : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q) - marketscreener.com
Cytosorbents Corp reports results for the quarter ended June 30Earnings Summary - TradingView
CytoSorbents Q2 2026 earnings: Margins improve despite flat revenue - TradingKey
CytoSorbents: Q2 Earnings Snapshot - marketscreener.com
Cytosorbents Corp 2Q 2026: Revenue $9.63M, EPS ($0.07) — 10-Q Summary - TradingView
Cytosorbents Corp. R (HQE1.DU) Q2 FY2026 earnings call transcript - Yahoo Finance
CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update - PR Newswire
CytoSorbents (Nasdaq: CTSO) flags going concern as cash falls to $5.9M - Stock Titan
Cytosorbents Corp expected to post a loss of 4 cents a shareEarnings Preview - TradingView
Cytosorbents Corp (CTSO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cytosorbents Corp (CTSO) Valuation: PE, PB & Fair Value Analysis - TradingKey
CytoSorbents Market Sentiment - Benzinga España
Cytosorbents Corp (CTSO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CTSO|Cytosorbents Corp|Price:0.360|Chg%:-0.001 - TradingKey
TradingKey - TradingKey
Cytosorbents Corp (CTSO) Cash Flow - TradingKey
CTSO|Cytosorbents Corp|Price:0.360| - TradingKey
Cytosorbents Corp (CTSO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CTSO|Cytosorbents Corp|Price:0.361|Chg%:-0.021 - TradingKey
CytoSorbents to Report Second Quarter 2026 Financial Results and Recent Business Highlights - BioSpace
CytoSorbents (CTSO) to Release Q2 Financial Results on July 30 - GuruFocus
CytoSorbents Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
CytoSorbents (NASDAQ: CTSO) falls below Nasdaq $35M value test, faces 180-day cure - Stock Titan
CTSO | Cytosorbents Corp. Executive Compensation - Quiver Quantitative
[ARS] Cytosorbents Corp SEC Filing - Stock Titan
CytoSorbents (NASDAQ: CTSO) seeks reverse split to support Nasdaq listing - Stock Titan
CytoSorbents (NASDAQ: CTSO) Targets Major ICU & Cardiac Surgery Markets With Breakthrough Blood Purification Tech, Eyes 2026 Cash Flow Breakeven and FDA Approval 246 - Minichart
CytoSorbents schedules two FDA pre-submission meetings for ticagrelor and DOAC programs - TradingView
CytoSorbents (NASDAQ: CTSO) details DrugSorb-ATR FDA meetings, sales and cash flow goals - Stock Titan
Cytosorbents Corp (CTSO) Institutional Confidence - TradingKey
Cytosorbents Corp (CTSO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Cytosorbents Corp 주식 (CTSO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Chan Phillip P. | Chief Executive Officer |
Jun 12 '26 |
Buy |
0.40 |
251,136 |
100,454 |
1,734,099 |
| Chan Phillip P. | Chief Executive Officer |
Jun 15 '26 |
Buy |
0.43 |
10,333 |
4,443 |
1,744,432 |
0.86%
0.13%
자본화:
|
볼륨(24시간):